Summary of Significant Accounting Policies - Collaboration Revenue (Details) $ in Thousands	1 Months Ended				3 Months Ended		9 Months Ended		22 Months Ended
	Jun. 30, 2016 USD ($)	Mar. 31, 2015 USD ($)	Sep. 30, 2014 USD ($)	May 31, 2014 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2015 USD ($)	Sep. 30, 2016 USD ($) category	Sep. 30, 2015 USD ($)	Jun. 30, 2016 USD ($)
Components of collaboration revenue
Total collaboration revenue					$ 1,668	$ 3,448	$ 45,587	$ 46,723
Number of categories for milestones | category							3
License revenue
Components of collaboration revenue
Total collaboration revenue					0	0	$ 22,937	38,083
Research and development activity revenue
Components of collaboration revenue
Total collaboration revenue					1,664	1,594	8,089	6,768
API transfer revenue
Components of collaboration revenue
Total collaboration revenue					0	1,851	14,545	1,851
Joint operating committee revenue
Components of collaboration revenue
Total collaboration revenue					$ 4	$ 3	$ 16	$ 21
Novartis Pharma AG | Licensing and Commercialization Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Upfront fees received				$ 200,000
Novartis Pharma AG | Licensing and Commercialization Agreement | Achievement of specified patient enrollment milestones
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Patient enrollment-based milestone revenue achieved	$ 30,000	$ 50,000	$ 50,000	30,000					$ 130,000
Milestone payment received				$ 130,000					$ 130,000